Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial.
Saved in:
| Title: | Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial. |
|---|---|
| Authors: | Powles T; Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, London; Royal Free National Health Service Trust, London, UK. Electronic address: thomas.powles1@nhs.net., Burotto M; Bradford Hill Clinical Research Center, Santiago, Chile., Escudier B; Gustave Roussy, Villejuif, France., Apolo AB; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA., Bourlon MT; Urologic Oncology Clinic, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico., Shah AY; MD Anderson Cancer Center, Houston, USA., Suárez C; Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Porta C; Department of Internal Medicine, University of Pavia, Pavia, Italy., Barrios CH; Centro de Pesquisa em Oncologia, Hospital São Lucas, PUCRS, Latin American Cooperative Oncology Group, Porto Alegre, Brazil., Richardet M; Fundación Richardet Longo, Instituto Oncológico de Córdoba, Córdoba, Argentina., Gurney H; Westmead Hospital and Macquarie University, Westmead and Sydney, Australia., Kessler ER; Division of Medical Oncology, Department of Internal Medicine, University of Colorado School of Medicine, Aurora, USA., Tomita Y; Departments of Urology and Molecular Oncology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan., Bedke J; Department of Urology, Eberhard Karls University Tübingen, Tübingen, Germany., George S; Roswell Park Comprehensive Cancer Center, Buffalo., Scheffold C; Exelixis, Inc., Alameda., Wang P; Bristol Myers Squibb, Princeton., Fedorov V; Bristol Myers Squibb, Princeton., Motzer RJ; Memorial Sloan Kettering Cancer Center, New York., Choueiri TK; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston; Brigham and Women's Hospital, Harvard Medical School, Boston, USA. |
| Source: | ESMO open [ESMO Open] 2024 May; Vol. 9 (5), pp. 102994. Date of Electronic Publication: 2024 Apr 20. |
| Publication Type: | Journal Article; Clinical Trial, Phase III; Randomized Controlled Trial; Multicenter Study |
| Journal Info: | Publisher: Elsevier Country of Publication: England NLM ID: 101690685 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2059-7029 (Electronic) Linking ISSN: 20597029 NLM ISO Abbreviation: ESMO Open Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
